Expanded FDI in Indian pharma raises government concerns

11/18/2013 | Economic Times (India), The

Foreign direct investment in India's pharmaceutical industry hit $1.07 billion from April to August, nearly double 2012 figures, triggering government calls to impose new restrictions such as mandatory R&D investment. There is also widespread concern that foreign acquisitions will affect the availability and affordability of generic drugs. India routinely permits 100% foreign investment in new pharmaceutical projects, but acquisitions of existing companies require approval by the Foreign Investment Promotion Board.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC